Pathologic parameters in the diagnosis and prognosis of primary cutaneous melanoma

Hematology/Oncology Clinics of North America

Volumn 12, Issue 4, 1998, Pages 717-735

  Randolph Byers, H ^a   Bhawan, J ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER STAGING; CARCINOGENESIS; DIAGNOSTIC VALUE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MELANOMA; MITOSIS; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; REVIEW; ULCER;

EID: 0031710009     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70020-4     Document Type: Article

References (65)

1. A.B. Ackerman Malignant melanoma: A unifying concept Hum Pathol 11 1980 591
2. A.B. Ackerman Discordance among expert pathologists in diagnosis of melanocytic neoplasms Hum Pathol 27 1996 1115
3. Akasaka T. van Leeuwen R.L. I.G. Yoshinaga Focal adhesion kinase (p125FAK) expression correlates with motility of human melanoma cell lines J Invest Dermatol 105 1995 104
4. C.M. Balch S.J. Soong T.M. Murad A multifactorial analysis of melanoma. II. Prognostic factors in patients with stage I (localized) melanoma Surgery 86 1979 343
5. C.M. Balch M.M. Urist C.P. Karakousis Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial Ann Surg 218 1993 262
6. R.L. Barnhill K. Fandrey M.A. Levy Angiogenesis and tumor progression of melanoma. Quantification of vascularity in melanocytic nevi and cutaneous malignant melanoma Lab Invest 67 1992 331
7. Barnhill R.L. Mihm M. Jr The histopathology of cutaneous malignant melanoma Semin Diagnost Pathol 10 1993 47
8. J. Bhawan Mel-5: A novel antibody for differential diagnosis of epidermal pigmented lesions of the skin in paraffin-embedded sections Melanoma Res 7 1997 43
9. K. Blessing K.M. McLaren A. McLean Thin malignant melanomas (less than 1.5 mm) with metastasis: A histological study and survival analysis Histopathology 17 1990 389
10. R. Boni A. Doguoglu G. Burg MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma J Am Acad Dermatol 35 1996 416
11. D. Bouffard L.M. Duncan C.A. Howard Actin-binding protein expression in benign and malignant melanocytic proliferations Hum Pathol 25 1994 709
12. A. Breslow Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma Ann Surg 172 1970 902
13. H.R. Byers M.C.J. Mihm Development of cell morphologic and molecular variables in melanoma prognosis Hori Y. Hearing V.J. Nakayama J. Melanogenesis and Malignant Melanoma: Biochemistry, Cell Biology, Molecular Biology, Pathophysiology, Diagnosis and Treatment 1996 Elsevier Science Amsterdam 205
14. S. Carrel J.F. Dore D.J. Ruiter The EORTC Melanoma Group exchange program: Evaluation of a multicenter monoclonal antibody study Int J Cancer 48 1991 836
15. Clark W. Jr What is inherited in neoplastic systems? Animal models of cutaneous malignant melanoma Lab Invest 71 1994 1
16. Clark W. Jr D.E. Elder Guerry D. IV Model predicting survival in stage I melanoma based on tumor progression J Natl Cancer Inst 81 1989 1893
17. Clark W. Jr L. From E.A. Bernardino The histogenesis and biologic behavior of primary human malignant melanomas of the skin Cancer Res 29 1969 705
18. C. Clemente A.J. Cochran D.E. Elder Histopathologic diagnosis of dysplastic nevi: Concordance among pathologists convened by the World Health Organization Melanoma Programme Hum Pathol 22 1991 313
19. C.C. Cunningham J.B. Gorlin D.J. Kwiatkowski Actin-binding protein requirement for cortical stability and efficient locomotion Science 255 1992 325
20. L.M. Duncan D. Bouffard C. Howard In situ distribution of integrin alpha 2 beta 1 and alpha-actinin in melanocytic proliferations Mod Pathol 9 1996 938
21. P.H. Duray J. Palazzo A.M. Gown Melanoma cell heterogeneity. A study of two monoclonal antibodies compared with S-100 protein in paraffin sections Cancer 61 1988 2460
22. D. Elder R. Elenitsas Benign pigmented lesions and malignant melanoma Elder D. Elenitsas R. Jaworsky C. Lever's Histopathology of the Skin ed 8 1997 Lippincott-Raven Philadelphia 625
23. D.E. Elder U. Rodeck J. Thurin Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas Cancer Res 49 1989 5091
24. M.E. Fallowfield M.G. Cook Vascular invasion in malignant melanomas An independent prognostic variable? Am J Surg Pathol 13 1989 217
25. E.R. Farmer R. Gonin M.P. Hanna Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists Hum Pathol 27 1996 528
26. V.H. Freedman S.I. Shin Cellular tumorigenicity in nude mice: Correlation with cell growth in semi-solid medium Cell 3 1974 355
27. R. Gaynor R. Irie D. Morton S100 protein is present in cultured human malignant melanomas Nature 286 1980 400
28. F.B. Geara K.K. Ang Radiation therapy for malignant melanoma Surg Clin North Am 76 1996 1383
29. A.M. Gown A.M. Vogel D. Hoak Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes Am J Pathol 123 1986 195
30. Greene M.H. Clark W. Jr M.A. Tucker High risk of malignant melanoma in melanoma-prone families with dysplastic nevi Ann Intern Med 102 1985 458
31. Guerry D. IV M. Synnestvedt D.E. Elder Lessons from tumor progression: The invasive radial growth phase of melanoma is common, incapable of metastasis, and indolent J Invest Dermatol 100 1993 342
32. M.N. Harris R.L. Shapiro D.F. Roses Malignant melanoma. Primary surgical management (excision and node dissection) based on pathology and staging Cancer 75 1995 715
33. T.J. Harrist D.S. Rigel Day C. Jr “Microscopic satellites” are more highly associated with regional lymph node metastases than is primary melanoma thickness Cancer 53 1984 2183
34. P.J. Heenan L.R. Matz J.B. Blackwell Inter-observer variation between pathologists in the classification of cutaneous malignant melanoma in western Australia Histopathology 8 1984 717
35. M. Herlyn J. Thurin G. Balaban Characteristics of cultured human melanocytes isolated from different stages of tumor progression Cancer Res 45 1985 5670
36. K. Itoh A.B. Tilden C.M. Balch Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas Cancer Res 46 1986 3011
37. S. Kang R.L. Barnhill Mihm M. Jr Histologic regression in malignant melanoma: An interobserver concordance study J Cutan Pathol 20 1993 126
38. A.B. Kanik M. Yaar J. Bhawan p75 nerve growth factor receptor staining helps identify desmoplastic and neurotropic melanoma J Cutan Pathol 23 1996 205
39. U. Kunter J. Buer M. Probst Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma J Natl Cancer Inst 88 1996 590
40. J.T. Kurnick R.L. Kradin R. Blumberg Functional characterization of T lymphocytes propagated from human lung carcinomas Clin Immunol Immunopathol 38 1986 367
41. P. Leon J.M. Daly M. Synnestvedt The prognostic implications of microscopic satellites in patients with clinical stage I melanoma Arch Surg 126 1991 1461
42. L. Li J.E. Price D. Fan Correlation of growth capacity of human tumor cells in hard agarose with their in vivo proliferative capacity at specific metastatic sites J Natl Cancer Inst 81 1989 1406
43. L.A. Liotta U. Wewer N.C. Rao Biochemical mechanisms of tumor invasion and metastases Adv Exp Med Biol 233 1988 161
44. J. Marcoval A. Moreno J. Graells Angiogenesis and malignant melanoma. Angiogenesis is related to the development of vertical (tumorigenic) growth phase J Cutan Pathol 24 1997 212
45. N.S. McNutt C. Urmacher J. Hakimian Nevoid malignant melanoma: Morphologic patterns and immunohistochemical reactivity J Cutan Pathol 22 1995 502
46. M. Miettinen K. Franssila Immunohistochemical spectrum of malignant melanoma. The common presence of keratins Lab Invest 61 1989 623
47. S. Moretti C. Pinzi E. Berti In situ expression of transforming growth factor beta is associated with melanoma progression and correlates with Ki67, HLA-DR and beta 3 integrin expression Melanoma Res 7 1997 313
48. N.G. Ordonez X.L. Ji R.C. Hickey Comparison of HMB-45 monoclonal antibody and S-100 protein in the immunohistochemical diagnosis of melanoma Am J Clin Pathol 90 1988 385
49. J.A. Ramsay L. From N.A. Iscoe MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas J Invest Dermatol 105 1995 22
50. V.B. Reddy P. Gattuso G. Aranha Cell proliferation markers in predicting metastases in malignant melanoma J Cutan Pathol 22 1995 248
51. D. Reintgen C.M. Balch J. Kirkwood Recent advances in the care of the patient with malignant melanoma Ann Surg 225 1997 1
52. S.G. Ronan A.M. Eng H.A. Briele Thin malignant melanomas with regression and metastases Arch Dermatol 123 1987 1326
53. J. Seykora D. Elder Dysplastic nevi and other risk markers for melanoma Semin Oncol 23 1996 682
54. H.M. Shaw C.M. Balch S.J. Soong Prognostic histopathological factors in malignant melanoma Pathology 17 1985 271
55. Slingluff C. Jr H.F. Seigler “Thin” malignant melanoma: Risk factors and clinical management Ann Plast Surg 28 1992 89
56. A. Slominski J. Ross M.C. Mihm Cutaneous melanoma: Pathology, relevant prognostic indicators and progression Br Med Bull 51 1995 548
57. S.J. Soong H.M. Shaw C.M. Balch Predicting survival and recurrence in localized melanoma: A multivariate approach World J Surg 16 1992 191
58. L. Talve H. Sauroja Y. Collan Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage Int J Cancer 74 1997 255
59. R.W. Tsang F.F. Liu W. Wells Lentigo maligna of the head and neck. Results of treatment by radiotherapy Arch Dermatol 130 1994 1008
60. U. Veronesi N. Cascinelli Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma Arch Surg 126 1991 438
61. U. Veronesi N. Cascinelli J. Adamus Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm N Engl J Med 318 1988 1159
62. Y. Wang D. Becker Differential expression of the cyclin-dependent kinase inhibitors p16 and p21 in the human melanocytic system Oncogene 12 1996 1069
63. Weterman M.A. van Muijen G.N. H.P. Bloemers Molecular markers of melanocytic tumor progression Lab Invest 70 1994 593
64. M.R. Wick P.E. Swanson A. Rocamora Recognition of malignant melanoma by monoclonal antibody HMB-45. An immunohistochemical study of 200 paraffin-embedded cutaneous tumors J Cutan Pathol 15 1988 201
65. A.J. Worth R.P. Gallagher J.M. Elwood Pathologic prognostic factors for cutaneous malignant melanoma: The Western Canada Melanoma Study Int J Cancer 43 1989 370